Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $28.1 million.

  • Akebia Therapeutics' Cash from Operations rose 51979.09% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 18414.59%. This contributed to the annual value of -$40.7 million for FY2024, which is 7387.53% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Cash from Operations is $28.1 million, which was up 51979.09% from $22.3 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Cash from Operations high stood at $33.8 million for Q3 2022, and its period low was -$70.7 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$13.6 million (2025), whereas its average is -$18.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 37737.67% in 2024, then soared by 51979.09% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Cash from Operations stood at -$62.8 million in 2021, then rose by 12.94% to -$54.7 million in 2022, then surged by 95.78% to -$2.3 million in 2023, then crashed by 93.5% to -$4.5 million in 2024, then surged by 729.31% to $28.1 million in 2025.
  • Its Cash from Operations stands at $28.1 million for Q3 2025, versus $22.3 million for Q2 2025 and -$13.6 million for Q1 2025.